We are live on ! Find out more
Cambridge Investment Research Advisors

Cambridge Investment Research Advisors Portfolio holdings

AUM $44.6B
1-Year Est. Return 28.94%
This Fund
S&P 500
This Quarter Est. Return
+3.51%
1 Year Est. Return
+28.94%
3 Year Est. Return
+82.62%
5 Year Est. Return
+90.41%
10 Year Est. Return
+293.66%
AUM
$4.72B
AUM Growth
+$298M
Cap. Flow
+$166M
Cap. Flow %
3.52%
Top 10 Hldgs %
20.14%
Holding
1,755
New
150
Increased
870
Reduced
476
Closed
198

Sector Composition

Rank Sector Weight
1 Consumer Staples 4.51%
2 Industrials 4.34%
3 Healthcare 4.27%
4 Communication Services 3.52%
5 Energy 3.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ACGN
1526
DELISTED
Aceragen Inc
ACGN
$28K ﹤0.01%
132
-30
-19% -$6.61K
ZN
1527
DELISTED
Zion Oil & Gas, Inc.
ZN
$26K ﹤0.01%
18,651
PLM
1528
DELISTED
PolyMet Mining Corp.
PLM
$26K ﹤0.01%
3,419
+9
+0.3% +$76
IMMU
1529
DELISTED
Immunomedics Inc
IMMU
$25K ﹤0.01%
+10,800
New +$36.1K
HEPA
1530
DELISTED
Hepion Pharmaceuticals
HEPA
0
EGY icon
1531
Vaalco Energy
EGY
$622M
$21K ﹤0.01%
20,130
-2,500
-11% -$2.67K
CRNT icon
1532
Ceragon Networks
CRNT
$192M
$17K ﹤0.01%
10,250
TURN
1533
DELISTED
180 Degree Capital
TURN
$17K ﹤0.01%
+3,455
New +$17.8K
XXII
1534
22nd Century Group
XXII
$1.5M
0
PARN
1535
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
$16K ﹤0.01%
+10,000
New +$18.4K
NMM icon
1536
Navios Maritime Partners
NMM
$2.24B
$15K ﹤0.01%
+769
New +$16.5K
QMCO icon
1537
Quantum Corp
QMCO
$464M
$13K ﹤0.01%
193
+63
+48% +$4.57K
NWBO
1538
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$13K ﹤0.01%
+21,600
New +$23.1K
PTX
1539
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$12K ﹤0.01%
+2,700
New +$17.6K
ARP
1540
DELISTED
ATLAS RESOURCE PARTNERS L P COM UIT REPSTG LTD PTNRS
ARP
$12K ﹤0.01%
21,898
+1,270
+6% +$654
SCON
1541
DELISTED
Superconductor Technologies Inc.
SCON
$11K ﹤0.01%
40
+20
+100% +$6.16K
IRD
1542
Opus Genetics
IRD
$304M
$9K ﹤0.01%
71
NAVB
1543
DELISTED
Navidea Biopharmaceuticals Inc.
NAVB
$9K ﹤0.01%
+838
New +$16.5K
REXX
1544
DELISTED
Rex Energy Corporation
REXX
$8K ﹤0.01%
+1,140
New +$9.5K
GAZ
1545
DELISTED
iPath Bloomberg Natural Gas Subindex Total Return ETN due October 22, 2037
GAZ
$7K ﹤0.01%
12,622
-700
-5% -$336
PVCT
1546
DELISTED
PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
$7K ﹤0.01%
18,824
+2,560
+16% +$974
PALI icon
1547
Palisade Bio
PALI
$365M
0
TWER
1548
DELISTED
Towerstream Corporation Common Stock
TWER
$4K ﹤0.01%
1,083
AA icon
1549
Alcoa
AA
$13.6B
-55,860
Closed -$1.29M
AAPL icon
1550
Apple
AAPL
$4.5T
-3,247,896
Closed -$88.5M

Similar funds

Cambridge Investment Research Advisors's Q2 2016 Portfolio in Review

As of Q2 2016, Cambridge Investment Research Advisors held 1,755 positions worth $4.72B, up 6.7% from $4.42B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Cambridge Investment Research Advisors deployed $166M of net new capital in Q2 2016, opening 150 new positions and adding to 870 existing holdings. Its largest new stake was Under Armour Class C: 94,246 shares worth $3.43M.

By sector, the portfolio is most concentrated in Consumer Staples at 4.5% of assets, up from 4.2% a quarter earlier, followed by Industrials and Healthcare.

On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $15.7M trimmed.

  • Cambridge Investment Research Advisors's largest Q2 2016 buy was Under Armour Class C: 94,246 shares worth $3.43M.
  • Cambridge Investment Research Advisors added most to Vanguard S&P 500 ETF in Q2 2016, an estimated $29.7M increase.
  • Cambridge Investment Research Advisors's biggest Q2 2016 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $15.7M.
  • Cambridge Investment Research Advisors fully exited Apple in Q2 2016, selling an estimated $88.5M.
  • Cambridge Investment Research Advisors's ten largest holdings make up 20% of its $4.72B portfolio in Q2 2016.
  • Cambridge Investment Research Advisors opened 150 new positions and closed 198 in Q2 2016.
  • Cambridge Investment Research Advisors's portfolio value rose 6.7% quarter-over-quarter to $4.72B.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2016, filed 4 Aug 2016.